Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

First patient dosed in phase II study of VRX-496 for HIV

Nov. 25, 2005

Transgene and IAVI sign manufacturing agreement

Nov. 22, 2005

TMC-125 begins phase III program

Nov. 21, 2005

tgAAC-09 begins phase II study in South Africa

Nov. 17, 2005

Novel agents for HIV infection imparted in recent patent literature

Nov. 16, 2005

FDA approval for new Kaletra tablets formulation

Nov. 10, 2005

Savvy phase III HIV prevention trial in Ghana to be discontinued

Nov. 10, 2005

HIV protease inhibitors imparted in recent Sequoia patent

Nov. 4, 2005

Tibotec opens U.S. expanded access program for TMC-114

Nov. 3, 2005

Cellegy completes enrollment in phase III HIV prevention study of Savvy

Nov. 2, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...